Search trials – HealthDB

Активни:

Намерени 3,079 изпитвания Стр. 6 от 154

Recruiting Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants

Healthy Volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants

Начало: 23.03.2026 Край: 01.07.2027 Възраст: 18–55 г. Basic science

Australia Meiji Pharma USA Inc. NCT07422207

Recruiting Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erthematosus (SLE) Lupus Nephritis (LN) Extra-renal Lupus (ERL)

This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with moderately to severely active systemic lupus erythematosus (SLE), including lupus nephritis and extra renal lupus. Approximately 30 participants will receive two intravenous doses of HB2198 and be followed for 12 months to assess safety, B cell depletion, disease activity, immunologic biomarkers, and renal outcomes.

Начало: 23.03.2026 Край: 24.10.2028 Възраст: 18–65 г. Treatment

Australia Hinge Bio NCT07491900

Recruiting Phase 3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Cardiovascular Disease

The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).

Начало: 23.03.2026 Край: 15.06.2028 Възраст: 35–80 г. Treatment

Australia, Canada, China +7 Amgen NCT07293260

Recruiting Phase 3

The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

Myopia Progression

The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children. The study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months. The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.

Начало: 21.03.2026 Край: 30.12.2026 Възраст: 7–11 г. Prevention

New Zealand Aston University NCT07535749

Recruiting Phase 1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Neisseria Meningitidis Serogroup B

A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.

Начало: 20.03.2026 Край: 01.07.2027 Възраст: 18–50 г. Prevention

Australia Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) NCT07395739

Recruiting Phase 1/2

Study in Advanced Solid Tumor Patients

Advanced Solid Tumor

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.

Начало: 19.03.2026 Край: 17.07.2028 Възраст: от 18 г. Treatment

Australia, United States Callio Therapeutics NCT07300943

Recruiting Phase 1

Single Ascending Dose Study of HB2198 in Healthy Participants

Healthy Volunteer

Phase 1, single center, randomized, double blind, placebo controlled SAD study assessing safety, tolerability, PK, PD, and immunogenicity of HB2198 after a single IV infusion in healthy adults. Four dose levels will be explored with sentinel participants per cohort. Approximately 32 participants (6 HB2198:2 placebo per cohort) will be followed for \~2 months, with extended follow up if B-cell counts remain suppressed.

Начало: 19.03.2026 Край: 21.08.2026 Възраст: до 55 г. Treatment

Australia Hinge Bio NCT07439263

Recruiting Phase 1

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

Alpha 1 Antitrypsin Deficiency

This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.

Начало: 17.03.2026 Край: 01.01.2029 Възраст: 18–74 г. Treatment

Australia, Georgia, United Kingdom AIRNA Corporation NCT07431112

Recruiting Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Epstein-Barr Virus

The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.

Начало: 17.03.2026 Край: 15.05.2027 Възраст: 18–30 г. Prevention

Australia ModernaTX, Inc. NCT07478952

Recruiting Phase 1

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Solid Tumors (Phase 1)

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Начало: 17.03.2026 Край: 14.03.2029 Възраст: от 18 г. Treatment

Australia, United States Adcendo ApS NCT07362888

Recruiting Phase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Начало: 16.03.2026 Край: 31.12.2033 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +27 Bristol-Myers Squibb NCT07361497

Recruiting Phase 1

A Study of ORN252 in Healthy Participants

Healthy Volunteers - Male and Female

The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.

Начало: 16.03.2026 Край: 01.03.2027 Възраст: 18–55 г. Basic science

Australia Orna Therapeutics, Inc. NCT07439796

Recruiting Phase 1

SAD and MAD Study of AKB-9090 in Healthy Adult Participants

Healthy Volunteers

This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.

Начало: 16.03.2026 Край: 01.12.2026 Възраст: 18–60 г. Treatment

New Zealand Akebia Therapeutics NCT07429006

Recruiting Phase 1/2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Начало: 16.03.2026 Край: 14.10.2031 Възраст: от 18 г. Treatment

Australia, Chile, China +10 Bristol-Myers Squibb NCT07291076

Recruiting Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

Ischemic Stroke

This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD, and active metabolites of LWP779 after oral administration in healthy participants.

Начало: 13.03.2026 Край: 30.09.2026 Възраст: 18–65 г. Treatment

Australia Longwood Pharmaceuticals (Hangzhou) Co., Ltd. NCT07371455

Recruiting Phase 2/3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

Начало: 13.03.2026 Край: 11.09.2032 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +17 Bristol-Myers Squibb NCT07221149

Recruiting Phase 2/3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Kidney Transplant Rejection

The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.

Начало: 13.03.2026 Край: 15.08.2033 Възраст: 18–70 г. Treatment

Australia, China Sanofi NCT07412470

Recruiting Phase 3

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Начало: 12.03.2026 Край: 14.10.2031 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +30 Bristol-Myers Squibb NCT07361510

Recruiting

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Stargardt Disease Retinitis Pigmentosa (RP) Inherited Retinal Degeneration

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.

Начало: 12.03.2026 Край: 01.03.2031 Възраст: от 18 г. Treatment

Australia Science Corporation NCT07266584

Recruiting Phase 1

Study of BW-50218 in Healthy Participants

Healthy Participants Study

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Начало: 12.03.2026 Край: 30.06.2027 Възраст: 18–65 г. Treatment

Australia Shanghai Argo Biopharmaceutical Co., Ltd. NCT07401472

1 … 4 5 6 7 8 … 154